ArticleBMC urology2026
Upregulation of osteopontin expression in prostatic stromal cells via the interaction with prostatic epithelial cells contribute to inflammation-related prostatic fibrosis.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to investigate the role of osteopontin (OPN) in promoting prostatic fibrosis through inflammation.
methodsOPN expression in the prostates of BPH patients was detected using immunohistochemistry, and its correlation with inflammatory grade, preoperative IPSS, and the percentage of collagen fiber was evaluated, respectively. RNA sequencing (RNA-Seq) identified differentially expressed genes (DEGs) in Spp1-OE WPMY-1 cells. A non-contact co-culture system of BPH-1 and WPMY-1 cells (with or without rhOPN treatment), Spp1-shRNA, or Spp1-OE WPMY-1 cells was established to assess WPMY-1 cells mRNA expression of PTGS2, CXCL1, CCL2, and Spp1 by RT-PCR.
resultsThe expression of OPN in prostate stromal cells was significantly higher in the symptomatic BPH (S-BPH) group, the IPSS 20-35 (severe symptom) group, and the Moderate + Severe inflammation group compared to the asymptomatic BPH (A-BPH) group, the IPSS 8-19 (moderate symptom) group, and the No + Mild inflammation group. Furthermore, OPN expression was positively correlated with preoperative IPSS and the percentage of collagen fibers in S-BPH patients. RNA-Seq identified some DEGs between Vector and Spp1-OE WPMY-1 cells, which are closely related to inflammation and fibrosis. In vitro experiments demonstrated that the expression of PTGS2, CXCL1, CCL2, and Spp1 significantly increased in WPMY-1 cells co-cultured with BPH-1 cells, particularly following treatment with rhOPN. Spp1-shRNA WPMY-1 cells co-cultured with BPH-1 cells exhibited reduced expression of PTGS2, CXCL1, and CCL2, whereas Spp1-OE WPMY-1 cells co-cultured with BPH-1 cells showed an increased expression of these genes.
conclusionsOPN may be involved in the occurrence of prostatic inflammation and fibrosis. The upregulation of OPN expression in prostatic stromal cells may contribute to prostatic fibrosis by interacting with prostatic epithelial cells to exacerbate inflammatory processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.